ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,930.85
1.09%
Dow Jones
42,840.26
1.18%
US Dollar vs MXN
20.0813
0.00%
Brent Oil
72.72
0.00%
Bitcoin
97,096.74
-0.11%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. NovoCure Ltd (NVCR) Cotización

NovoCure Ltd

NovoCure Ltd (NVCR)

NASDAQ
30.80
0.40
(1.32%)
Cerrado 22 Diciembre 3:00PM
Delayed by 15 minutes
30.8005
0.0005
(0.00%)
Fuera de horario: 6:59PM
Delayed by 15 minutes

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Premium

Estadísticas y detalles clave

Último Precio
30.80
Postura de Compra
30.50
Postura de Venta
84.37
Volume Operado de la Acción
1,820,760
30.33 Rango del Día 31.52
11.70 Rango de 52 semanas 34.13
Capitalización de Mercado [m]
3.333B
Precio Anterior
30.40
Precio de Apertura
30.33
Hora
10
@
30.99
Última hora de negociación
Volumen financiero
US$ 55,880,217
Precio Promedio Ponderado
30.6906
Volumen promedio (3 m)
1,348,273
Acciones en circulación
108,201,434
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-16.11
Beneficio por acción (BPA)
-1.91
turnover
509.34M
Beneficio neto
-207.04M

Acerca de NovoCure Ltd

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives it... NovoCure Ltd serves in the healthcare sector of the United States. Its business involves commercial-stage oncology operations involving therapies to cure critical tumors. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. NovoCure derives its major revenues in the United States. Mostrar más

Sector
Surgical,med Instr,apparatus
Industria
Surgical,med Instr,apparatus
Sitio web
www.novocure.com
Sede
Jersey, Gbr
Fundado
-
NovoCure Ltd is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker NVCR. The last closing price for NovoCure was US$30.40. Over the last year, NovoCure shares have traded in a share price range of US$ 11.70 to US$ 34.13.

NovoCure currently has 108,201,434 shares in issue. The market capitalisation of NovoCure is US$3.29 billion. NovoCure has a price to earnings ratio (PE ratio) of -16.11.

NVCR Últimas noticias

Más noticias

Novocure annonce des résultats positifs de l'essai clinique de phase 3 PANOVA-3 sur les champs de traitement des tumeurs (TTFields) pour le cancer du pancréas

PANOVA-3 a atteint son objectif principal avec une amélioration statistiquement importante de la survie globale des patients atteints d'un adénocarcinome pancréatique non résécable et localement...

05 Diciembre 2024
Business Wire

ノボキュア、膵がんに対する腫瘍治療電場療法（TTフィールド）の第3相臨床試験PANOVA-3のトップライン結果を発表

PANOVA-3試験でゲムシタビンおよびnab-パクリタキセルと併用したTTフィールドを一次治療として用いた切除不能な局所進行膵腺がん患者の全生存期間が統計的に有意に改善、主要評価項目を達成 アメリカ、EU、日本...

04 Diciembre 2024
Business Wire

Zai Lab and Novocure Announce Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

PANOVA-3 met its primary endpoint with a statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma treated in the...

02 Diciembre 2024
Business Wire

Form 8-K - Current report

02 Diciembre 2024
Edgar (US Regulatory)

Novocure Announces Positive Topline Results from Phase 3 PANOVA-3 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer

PANOVA-3 met its primary endpoint with a statistically significant improvement in overall survival for patients with unresectable, locally advanced pancreatic adenocarcinoma treated in the first...

02 Diciembre 2024
Business Wire

Novocure to Participate in Upcoming Investor Conferences

Novocure (NASDAQ: NVCR) announced today that management will participate in two upcoming investor conferences: Evercore ISI HealthCONx Conference on Wednesday, December 4, 2024, in Coral Gables...

27 Noviembre 2024
Business Wire

Novocure Data at 2024 SNO Annual Meeting Highlights Product Innovation and Real-World Evidence for Tumor Treating Fields (TTFields) Therapy in Glioblastoma

Novocure (NASDAQ: NVCR) announced today that it will present new data for its Tumor Treating Fields (TTFields) therapy for glioblastoma at the 29th Annual Scientific Meeting and Education Day of...

21 Noviembre 2024
Business Wire

FDA Approves Novocure’s Innovative HFE Transducer Arrays for Use With Optune Gio® for Glioblastoma

New flexible arrays are lighter, thinner and designed to improve comfort for Optune Gio users Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) approved its...

21 Noviembre 2024
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

06 Noviembre 2024
Edgar (US Regulatory)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.050.16260162601630.7534.1329.79140811331.91125459CS
413.6179.173938336217.1934.1317.16192650228.83293627CS
1214.7992.379762648316.0134.1314.17134827322.28694961CS
2611.660.416666666719.234.1314.17132390320.11071264CS
5217.27127.64227642313.5334.1311.7132937418.09382564CS
156-53.01-63.250208805683.81120.0310.87109603538.33953569CS
260-54.55-63.913298183985.35232.7610.87100974967.17234781CS

NVCR - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de NovoCure?
El precio actual de las acciones de NovoCure es US$ 30.80
¿Cuántas acciones de NovoCure están en circulación?
NovoCure tiene 108,201,434 acciones en circulación
¿Cuál es la capitalización de mercado de NovoCure?
La capitalización de mercado de NovoCure es USD 3.29B
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de NovoCure?
NovoCure ha negociado en un rango de US$ 11.70 a US$ 34.13 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de NovoCure?
El ratio precio/beneficio de NovoCure es -16.11
¿Cuál es el ratio de efectivo a ventas de NovoCure?
El ratio de efectivo a ventas de NovoCure es 6.55
¿Cuál es la moneda de reporte de NovoCure?
NovoCure presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de NovoCure?
El último ingresos anual de NovoCure es USD 509.34M
¿Cuál es el último beneficio anual de NovoCure?
El último beneficio anual de NovoCure es USD -207.04M
¿Cuál es la dirección registrada de NovoCure?
La dirección registrada de NovoCure es NO 4 THE FORUM, GRENVILLE STREET, ST. HELIER, JERSEY, JE2 4UF
¿Cuál es la dirección del sitio web de NovoCure?
La dirección del sitio web de NovoCure es www.novocure.com
¿En qué sector industrial opera NovoCure?
NovoCure opera en el sector SURGICAL,MED INSTR,APPARATUS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
MYSZMy Size Inc
US$ 4.2001
(211.12%)
121.03M
NVNINVNI Group Ltd
US$ 8.26
(209.36%)
78.06M
TPICTPI Composites Inc
US$ 2.45
(100.82%)
34M
ICGIntchains Group Ltd
US$ 8.77
(88.60%)
527.94k
HSDTHelius Medical Technologies Inc
US$ 0.884851
(84.34%)
121.95M
CYNCYNGN Inc
US$ 0.4603
(-71.41%)
27.5M
MTEMMolecular Templates Inc
US$ 0.1502
(-57.09%)
8.63M
PRFXPainReform Ltd
US$ 5.15
(-53.85%)
2.84M
GALTGalectin Therapeutics Inc
US$ 1.03
(-48.50%)
8.58M
BCABBioAtla Inc
US$ 0.6923
(-41.82%)
5.96M
EDBLEdible Garden AG Inc
US$ 0.24
(65.06%)
354.33M
NVDANVIDIA Corporation
US$ 134.70
(3.08%)
310.19M
APTOAptose Biosciences Inc
US$ 0.28
(64.51%)
306.25M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0.606999
(6.49%)
293.22M
PLTRPalantir Technologies Inc
US$ 80.55
(8.54%)
281.23M

NVCR Discussion

Ver más
whosleftholdindabag whosleftholdindabag 1 semana hace
$NVCR has reached its 52-week high! Wishing everyone a great weekend! GLTA
👍️0
PonkenPlonken PonkenPlonken 3 semanas hace
Thank you for sharing!
They seem to believe this makes it to market in CRC is my read.
👍️0
jondoeuk jondoeuk 3 semanas hace
A phase 2 trial, PANOVA-4, will test TTFields combined with a triplet regimen of gemcitabine, nab-paclitaxel and atezolizumab as a first-line treatment for metastatic pancreatic ductal adenocarcinoma. It has completed enrolment and the company said it expects to have data in 2026.

The primary endpoint is disease control rate (DCR). Secondary endpoints include, overall survival (OS), progression-free survival (PFS), 1-year OS rate, objective response rate (ORR), PFS at 6 months, duration of response, and safety.
👍️0
whosleftholdindabag whosleftholdindabag 3 semanas hace
$NVCR what a great way to kick off December, don't you know? Where are all the bloody naysayers today? We're raising a lot of money for charity! GLTA
👍️0
jondoeuk jondoeuk 3 semanas hace
Novocure plans to file for regulatory approval in the U.S., EU, Japan and other key markets; Zai Lab plans to file for regulatory approval in China https://www.businesswire.com/news/home/20241202363277/en/Zai-Lab-and-Novocure-Announce-Positive-Topline-Results-from-Phase-3-PANOVA-3-Clinical-Trial-of-Tumor-Treating-Fields-TTFields-Therapy-for-Pancreatic-Cancer
👍️ 1
tw0122 tw0122 3 semanas hace
Looking good $30 +
50% 
12:09 PM EST, 12/02/2024 (MT Newswires) -- (Updates with stock move in the headline and first paragraph.)NovoCure's (NVCR) shares rose more than 41% in recent Monday trading after the company and Zai Lab (ZLAB) said that their phase 3 trial evaluating TTFields along with gemcitabine and nab-paclitaxel as a treatment for unresectable, locally advanced pancreatic adenocarcinoma achieved its primary endpoint, demonstrating a "statistically significant" improvement in median overall survival.NovoCure (NVCR) plans regulatory filings in the US, EU, Japan, and other major markets, while Zai Lab plans to file for regulatory approval in China, the companies said.
👍️0
PonkenPlonken PonkenPlonken 3 semanas hace
would love to see new session high
data is hot --- Can become SOC
👍️0
whosleftholdindabag whosleftholdindabag 3 semanas hace
$NVCR back above $20! GLTA
👍️0
Invest-in-America Invest-in-America 2 meses hace
NVCR: One has to be patently BRAIN DEAD to attribute any significance whatsoever to the 1890's-like ELECTRICAL, cure-all, gadgets that this obvious SCAM company promotes!!!
👍️ 1
jondoeuk jondoeuk 2 meses hace
FDA Approves Novocure’s Optune Lua for the Treatment of Metastatic Non-Small Cell Lung Cancer https://www.businesswire.com/news/home/20241015381082/en
👍️ 1 💥 1
whosleftholdindabag whosleftholdindabag 2 meses hace
Lovely action AH $NVCR! I can't wait for the opening bell, wishing everyone a great evening! GLTA
👍️0
whosleftholdindabag whosleftholdindabag 2 meses hace
$NVCR great way to end the trading day! GLTA
👍️0
whosleftholdindabag whosleftholdindabag 2 meses hace
I own both $NVCR and $NWBO, all proceeds will go to charity. GLTA
👍️0
KIPK KIPK 2 meses hace
Glad to see you are in the right stock, NWBO, now!!
👍️0
TiltMyBrain TiltMyBrain 4 meses hace
Who is the bag holder now???

Going to single digits
👍️ 1
whosleftholdindabag whosleftholdindabag 5 meses hace
Come fly with me, let's fly let's fly away! Ol blue eyes, what a beautiful voice! Great start $NVCR! GLTA
🚽 2
whosleftholdindabag whosleftholdindabag 5 meses hace
Back above $20 $NVCR! GLTA
🚽 1
whosleftholdindabag whosleftholdindabag 7 meses hace
Another week, another beautiful day for $NVCR shareholders! GLTA
🐀 1
whosleftholdindabag whosleftholdindabag 7 meses hace
Another beautiful start of the week for $NVCR! GLTA
😂 1
KIPK KIPK 7 meses hace
LOL - Go from over $200 to $20.
Wondering why this charity worker is NWBO hater.
Wondering why a self proclaimed good spirit tries so hard to destroy a great cancer therapy company. NWBO, hat is not NVCR??
A true charity worker expected to be compassionate, caring, and greatful of all possible potentials...

BUT not this guy??

You judge!!!

KARMA!!
👍️ 3 💯 2
whosleftholdindabag whosleftholdindabag 7 meses hace
GO $NVCR GO! We're making A LOT of $$$$$ for charities don't you know? GLTA
⚠️ 1
whosleftholdindabag whosleftholdindabag 7 meses hace
Beautiful day $NVCR! GLTA
👎️ 2 🤣 2
whosleftholdindabag whosleftholdindabag 7 meses hace
It's been another great week for $NVCR! Have a wonderful weekend everyone! GLTA
👎️ 2 🚫 1 🤣 1
TiltMyBrain TiltMyBrain 7 meses hace
Insiders to sell shares in 30 days
👍️ 2 💥 2
KIPK KIPK 8 meses hace
LOL 🤣🤣🤣
👍️ 2 💯 1
dstock07734 dstock07734 8 meses hace
Or you can simply wait.
👍️ 1 🤣 2
whosleftholdindabag whosleftholdindabag 8 meses hace
Well that's fantastic mate! Perhaps I'll have my lawyer contact her, have a great weekend! GLTA
🤣 1 ⚠️ 1
dstock07734 dstock07734 8 meses hace
By now, you should be smart enough to know that Laura Posner or Elliott Leary would be able to get IP address of each poster on NWBO board.
👍️ 4
dstock07734 dstock07734 8 meses hace
libel? Which part is libel? Nemesis18's post style is very similar to yours, would you agree?
👍️ 3 🤣 2
whosleftholdindabag whosleftholdindabag 8 meses hace
No, do you? GLTA
⚠️ 1
whosleftholdindabag whosleftholdindabag 8 meses hace
I'd be careful you're getting a wee bit close to libel don't you know? GLTA
🚫 1 🤣 1
whosleftholdindabag whosleftholdindabag 8 meses hace
Great way to end the week! Finish strong $NVCR! Have a great weekend everyone! GLTA
🚫 1 🤣 1
whosleftholdindabag whosleftholdindabag 8 meses hace
You're posting on the wrong board mate, $NWBO is the one dealing with toxic financers go over there and post your rubbish! GLTA

Streeterville Capital, LLC is a Chicago-based company owned by John M. Fife, who has been described as a "toxic lender" for many years. Toxic financing is a type of financing that companies use when they are in poor condition and can't get financing in any other way. It can come in the form of convertible debt or convertible preferred stock and often gives the debtholder an unlimited number of common shares when they convert their debt or preferred shares to common stock.
👍️ 1
TiltMyBrain TiltMyBrain 8 meses hace
Toxic financing for a company who’s price is down 90% in last 3 years
👍️ 2 💥 2
TiltMyBrain TiltMyBrain 8 meses hace
Today is the pump. Tomorrow is the insider dump
👍️ 2 💥 2
KIPK KIPK 8 meses hace
What a great day right Nemeses 18?
How is dat charity holding da bag???
👍️ 2 😂 2 🤣 1
KIPK KIPK 8 meses hace
Gone with the wind on wings of fake therapy IMO
👍️ 2 💯 1
KIPK KIPK 9 meses hace
20? including a PRE-CLINICAL???? lol
And all that unfocused activity signal the total desperation to keep the SP up IMO...

Reminds me of INO, which also kept throwing stuff at every possible thing, hoping one would stick.... But NO... INO SP at one time was over $2000 & now is around $11 after a recent RS
👍️ 1
axelvento axelvento 9 meses hace
Novocure Announces 20 Presentations On Tumor Treating Fields, Highlighting Preclinical Effects in Pancreatic Cancer and Immune Effects, at American Association for Cancer Research (AACR) Annual Meeting 2024

https://www.biospace.com/article/releases/novocure-announces-20-presentations-on-tumor-treating-fields-highlighting-preclinical-effects-in-pancreatic-cancer-and-immune-effects-at-american-association-for-cancer-research-aacr-annual-meeting-2024/
👎️ 2 🤣 1
TiltMyBrain TiltMyBrain 9 meses hace
https://x.com/peter_brit/status/1775041789889491437?s=46&t=1nHn7IXseo2gJ7ymtRCgUA

This ship is sinking fast!
👍️ 3 👏 3
TiltMyBrain TiltMyBrain 9 meses hace
insider selling in 3...2...1...
👍️ 3 💯 3 😂 1 🤣 1
TiltMyBrain TiltMyBrain 9 meses hace
"Preliminary analyses of key secondary endpoints (time to neurocognitive failure, overall survival, and radiological response rate) did not demonstrate statistical significance."

pump and dump in progress
👍️ 2 💯 2 🤣 1
whosleftholdindabag whosleftholdindabag 9 meses hace
Loving the early action on $NVCR. Wishing everybody a great day! GLTA
🐀 1 🗑️ 1 🤣 2
KIPK KIPK 9 meses hace
LOL - "In time to Intracranial Progression" ??? SMH
👍️ 1
Awl416 Awl416 9 meses hace
METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
👍️ 2 💯 1
KIPK KIPK 9 meses hace
The Vanishing tin can on the wind of ineffectiveness!!
Have a kick at it MATE - LOL !!
👍️ 1
KIPK KIPK 9 meses hace
You just made a positive post for NWBO without knowing it MATE. Think JAMA.....

And that's So sad as You must be in total loss for words to be citing here a post by a Paid NWBO Basher, InquiriNg. At least you should have given the credit as she, just like you, has been lost for words as well MATE!! . LOL Mate!!

You Birt got nothing & the tin hat is made for a tin man... just like you & the charity investor scamwannabe!!
LOL
👍️ 4 🤣 2
jondoeuk jondoeuk 9 meses hace
NWBO's DCVax-L is an expensive placebo. The same is true for DCVax-Direct.
👍️ 1 💯 1 🗑️ 3 ❌️ 2
KIPK KIPK 9 meses hace
Congrats whosbagholding. You keep expanding your reach into Charity Work. LOL - SMH...

Below is a response to one of your good will intention (LOL) on NWBO MB>>>>
Re: AAPL31415926 post# 679357

Monday, March 18, 2024 8:40:02 AM

Post#
679360
of 679363
Amazing that whosbagholding gave me a clown emoji on this comment. It shows how absolutely evil these people are. Hopefully he/she/it/they don't have to face their spouse or one of their children being diagnosed with a fatal disease that they work hard to try and destroy a cure for. Then again there's always karma.
👍️0
KIPK KIPK 10 meses hace
Who S Left Hold In D Bag - LOL LOL LOL LOL - Brit Mate?? LOL
👍️ 2 🤣 2

Su Consulta Reciente

NASDAQ
NVCR
NovoCure
NASDAQ
FDRDX
Bmo Growth and Income Fu...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados